208 related articles for article (PubMed ID: 11237835)
41. Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans.
Fries BC; Cook E; Wang X; Casadevall A
Antimicrob Agents Chemother; 2005 Jan; 49(1):350-7. PubMed ID: 15616315
[TBL] [Abstract][Full Text] [Related]
42. Effect of amphotericin B on capsule and cell size in Cryptococcus neoformans during murine infection.
Zaragoza O; Mihu C; Casadevall A; Nosanchuk JD
Antimicrob Agents Chemother; 2005 Oct; 49(10):4358-61. PubMed ID: 16189121
[TBL] [Abstract][Full Text] [Related]
43. Effects of voriconazole on Cryptococcus neoformans.
van Duin D; Cleare W; Zaragoza O; Casadevall A; Nosanchuk JD
Antimicrob Agents Chemother; 2004 Jun; 48(6):2014-20. PubMed ID: 15155193
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of SPK-843, a novel polyene antifungal, in a murine model of systemic cryptococcosis.
Kakeya H; Miyazaki Y; Senda H; Kobayashi T; Seki M; Izumikawa K; Yamamoto Y; Yanagihara K; Tashiro T; Kohno S
Antimicrob Agents Chemother; 2008 May; 52(5):1871-2. PubMed ID: 18299408
[TBL] [Abstract][Full Text] [Related]
45. Effective inhibition of Cbf-14 against Cryptococcus neoformans infection in mice and its related anti-inflammatory activity.
Yu C; Wei S; Han X; Liu H; Wang M; Jiang M; Guo M; Dou J; Zhou C; Ma L
Fungal Genet Biol; 2018 Jan; 110():38-47. PubMed ID: 29221882
[TBL] [Abstract][Full Text] [Related]
46. Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection.
Rosas AL; Nosanchuk JD; Casadevall A
Infect Immun; 2001 May; 69(5):3410-2. PubMed ID: 11292764
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of the anticryptococcal activity of the antibiotic polymyxin B in vitro and in vivo.
Zhai B; Lin X
Int J Antimicrob Agents; 2013 Mar; 41(3):250-4. PubMed ID: 23313397
[TBL] [Abstract][Full Text] [Related]
48. [Effect of 4B3 monoclonal antibody on the experimental Cryptococcus neoformans infection].
Illnait-Zaragozí MT; Gato Armas R; Martínez Machín GF; Otero González A; Sarracent Pérez J; Rodríguez Sánchez H; Fernández Andreu CM; Valdés Hernández Idel C
Rev Cubana Med Trop; 2011; 63(2):123-9. PubMed ID: 23437519
[TBL] [Abstract][Full Text] [Related]
49. Conditional lethality of the diprotic weak bases chloroquine and quinacrine against Cryptococcus neoformans.
Harrison TS; Griffin GE; Levitz SM
J Infect Dis; 2000 Jul; 182(1):283-9. PubMed ID: 10882608
[TBL] [Abstract][Full Text] [Related]
50. Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis.
Mylonakis E; Ausubel FM; Perfect JR; Heitman J; Calderwood SB
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15675-80. PubMed ID: 12438649
[TBL] [Abstract][Full Text] [Related]
51. Cryptococcus neoformans laccase catalyses melanin synthesis from both D- and L-DOPA.
Eisenman HC; Mues M; Weber SE; Frases S; Chaskes S; Gerfen G; Casadevall A
Microbiology (Reading); 2007 Dec; 153(Pt 12):3954-3962. PubMed ID: 18048910
[TBL] [Abstract][Full Text] [Related]
52. A potential of propolis on major virulence factors of Cryptococcus neoformans.
Thammasit P; Iadnut A; Mamoon K; Khacha-Ananda S; Chupradit K; Tayapiwatana C; Kasinrerk W; Tragoolpua Y; Tragoolpua K
Microb Pathog; 2018 Oct; 123():296-303. PubMed ID: 30041002
[TBL] [Abstract][Full Text] [Related]
53. Laccase and melanin in the pathogenesis of Cryptococcus neoformans.
Williamson PR
Front Biosci; 1997 Nov; 2():e99-107. PubMed ID: 9342305
[TBL] [Abstract][Full Text] [Related]
54. Melanisation of Cryptococcus neoformans in human brain tissue.
Nosanchuk JD; Rosas AL; Lee SC; Casadevall A
Lancet; 2000 Jun; 355(9220):2049-50. PubMed ID: 10885360
[TBL] [Abstract][Full Text] [Related]
55. Glyphosate inhibits melanization and increases susceptibility to infection in insects.
Smith DFQ; Camacho E; Thakur R; Barron AJ; Dong Y; Dimopoulos G; Broderick NA; Casadevall A
PLoS Biol; 2021 May; 19(5):e3001182. PubMed ID: 33979323
[TBL] [Abstract][Full Text] [Related]
56. Cryptococcal therapies and drug targets: the old, the new and the promising.
Coelho C; Casadevall A
Cell Microbiol; 2016 Jun; 18(6):792-9. PubMed ID: 26990050
[TBL] [Abstract][Full Text] [Related]
57. Immunomodulator tuftsin increases the susceptibility of Cryptococcus neoformans to liposomal amphotericin B in immunocompetent BALB/c mice.
Khan MA; Owais M
J Drug Target; 2005 Aug; 13(7):423-9. PubMed ID: 16308211
[TBL] [Abstract][Full Text] [Related]
58. Melanization in Cryptococcus neoformans Requires Complex Regulation.
Cordero RJB; Camacho E; Casadevall A
mBio; 2020 Feb; 11(1):. PubMed ID: 32019794
[TBL] [Abstract][Full Text] [Related]
59. Laccase protects Cryptococcus neoformans from antifungal activity of alveolar macrophages.
Liu L; Tewari RP; Williamson PR
Infect Immun; 1999 Nov; 67(11):6034-9. PubMed ID: 10531264
[TBL] [Abstract][Full Text] [Related]
60. Development of nose-to-brain delivery of ketoconazole by nanostructured lipid carriers against cryptococcal meningoencephalitis in mice.
Du W; Li H; Tian B; Sai S; Gao Y; Lan T; Meng Y; Ding C
Colloids Surf B Biointerfaces; 2019 Nov; 183():110446. PubMed ID: 31465938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
